This is the authors' abstract. We don't add key points for this paper.
BACKGROUND: Congenital cytomegalovirus is the leading cause of nongenetic sensorineural hearing loss. Treatment with (val)ganciclovir improves audiologic outcomes. Neutropenia is a common adverse event, but correlates that predict who will develop neutropenia have not been identified. METHODS: Data from 3 National Institutes of Health-funded studies of intravenous ganciclovir or oral valganciclovir were evaluated. Baseline absolute neutrophil count (ANC) was defined as high (ANC >1000 cells/mm 3 ) or low (ANC ≤1000 cells/mm 3 ), and neutropenia was defined as ANC <800 cells/mm 3 . Mean 12-hour area under the curve (AUC 12 ) ganciclovir values were analyzed as a function of degree of neutropenia using analysis of variance. AUC 12 values ≥40 mgxhr/L were defined as high drug exposure and <40 mgxhr/L as low drug exposure. RESULTS: Of 134 subjects who had AUC 12 values obtained during the first week of treatment, 61 (46%) developed neutropenia <800 cells/mm 3 . Infants with high drug exposure developed neutropenia more rapidly than subjects with low drug exposure (median of 28 vs. 216 days; P < 0.008). Although not significant, infants with a baseline ANC ≤1000 cells/mm 3 were observed to develop neutropenia more rapidly compared with those with a high baseline ANC (estimated median of 69 vs. 216 days; P = 0.22) and in greater proportions, although not statistically significant [55.6% vs. 39.3%; P = 0.21; odds ratio, 1.9 (95% CI, 0.71-5.20)]. CONCLUSIONS: High AUC 12 correlated with the development of neutropenia in infants treated for symptomatic congenital cytomegalovirus disease. Low baseline ANC also may contribute to the development of neutropenia.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Nishikawa et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: